Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disorder caused by a mutation in the PIGA gene. This mutation causes defective hematopoietic stem cells, which develop into defective red blood ...
Older AA/PNH patients who have myeloid driver mutations at baseline and a poor response to nontransplant treatment have a higher risk of progression to sMN. Baseline-prevalent mutations (PIGA/human ...
A retrospective analysis surveys the treatment landscape and patterns of patients with paroxysmal nocturnal hemoglobinuria (PNH), illuminating high hospitalization rates and emergency department use ...
The FDA approved the complement C5 inhibitor crovalimab (Piasky) for treating paroxysmal nocturnal hemoglobinuria (PNH), a rare but life-threatening blood disease. Indicated for PNH in adults and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results